OTCPK:GSGT.F

Stock Analysis Report

Executive Summary

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.

Snowflake

Fundamentals

Mediocre balance sheet with limited growth.

Share Price & News

How has GenSight Biologics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:GSGT.F

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

n/a

OTCPK:GSGT.F

-8.0%

US Biotechs

-0.5%

US Market

No trading data on GSGT.F.

No trading data on GSGT.F.


Share holder returns

GSGT.FIndustryMarket
7 Day0%0.5%-0.7%
30 Day0%1.0%-3.0%
90 Day-7.7%3.2%0.9%
1 Yearn/a-7.3%-8.0%1.7%-0.5%
3 Yearn/a9.3%5.6%39.5%30.4%
5 Yearn/a7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is GenSight Biologics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is GenSight Biologics undervalued based on future cash flows and its price relative to the stock market?

1.52x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for GenSight Biologics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for GenSight Biologics to establish if it is available at substantial discount.


Price Based on Earnings

GenSight Biologics is loss making, we can't compare its value to the US Biotechs industry average.

GenSight Biologics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for GenSight Biologics, we can't assess if its growth is good value.


Price Based on Value of Assets

GenSight Biologics is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is GenSight Biologics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

31.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

GenSight Biologics's revenue is expected to grow significantly at over 20% yearly.

GenSight Biologics is not considered high growth as it is expected to be loss making for the next 1-3 years.

GenSight Biologics's revenue growth is expected to exceed the United States of America market average.

Unable to compare GenSight Biologics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare GenSight Biologics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if GenSight Biologics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has GenSight Biologics performed over the past 5 years?

-30.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

GenSight Biologics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare GenSight Biologics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare GenSight Biologics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if GenSight Biologics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if GenSight Biologics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if GenSight Biologics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is GenSight Biologics's financial position?


Financial Position Analysis

GenSight Biologics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

GenSight Biologics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

GenSight Biologics's level of debt (14.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (1% vs 14.4% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 10.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

GenSight Biologics has less than a year of cash runway based on current free cash flow.

GenSight Biologics has less than a year of cash runway if free cash flow continues to grow at historical rates of 22% each year.


Next Steps

Dividend

What is GenSight Biologics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate GenSight Biologics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate GenSight Biologics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as GenSight Biologics has not reported any payouts.

Unable to verify if GenSight Biologics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as GenSight Biologics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of GenSight Biologics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of GenSight Biologics's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Bernard Gilly (62yo)

7.6yrs

Tenure

€628,518

Compensation

Dr. Bernard Gilly, Ph.D. serves as Chairman at iBionext. He serves as President and Chairman of the Board at ChronoLife SAS. He co-founded Fovea Pharmaceuticals, SA in 2005 and serves as its Chairman, Chie ...


CEO Compensation Analysis

Bernard's remuneration is higher than average for companies of similar size in United States of America.

Bernard's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.0yrs

Average Tenure

The tenure for the GenSight Biologics management team is about average.


Board Age and Tenure

7.3yrs

Average Tenure

64yo

Average Age

The tenure for the GenSight Biologics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Bernard Gilly (62yo)

    Co-Founder

    • Tenure: 7.6yrs
    • Compensation: €628.52k
  • José-Alain Sahel

    Scientific Founder

    • Tenure: 0.0yrs
  • Barrett Katz

    Chief Medical Officer

    • Tenure: 1.8yrs
  • Connie Cepko

    Scientific Founders & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Botond Roska

    Scientific Founder & Chairman of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jean Bennett

    Scientific Founder & Vice Chairman of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Luk Vandenberghe

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Serge Picaud

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Thomas Gidoin (36yo)

    Chief Financial Officer

    • Tenure: 4.1yrs
  • Julio Benedicto

    Vice President of Marketing

    • Tenure: 1.6yrs

Board Members

  • Mike Wyzga (64yo)

    Chairman of the Board

    • Tenure: 3.4yrs
    • Compensation: €165.35k
  • Bernard Gilly (62yo)

    Co-Founder

    • Tenure: 7.6yrs
    • Compensation: €628.52k
  • Peter Goodfellow (68yo)

    Independent Director

    • Tenure: 0.0yrs
    • Compensation: €60.00k
  • José-Alain Sahel

    Scientific Founder

    • Tenure: 0.0yrs
  • Connie Cepko

    Scientific Founders & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Botond Roska

    Scientific Founder & Chairman of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Jean Bennett

    Scientific Founder & Vice Chairman of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Luk Vandenberghe

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Serge Picaud

    Scientific Founder & Member of Scientific Advisory Board

    • Tenure: 7.3yrs
  • Ernst Bamberg

    Member of Scientific Advisory Board

    • Tenure: 7.3yrs

Company Information

GenSight Biologics S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GenSight Biologics S.A.
  • Ticker: GSGT.F
  • Exchange: OTCPK
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €42.498m
  • Listing Market Cap: €47.157m
  • Shares outstanding: 28.91m
  • Website: https://www.gensight-biologics.com

Number of Employees


Location

  • GenSight Biologics S.A.
  • 74, rue du Faubourg Saint-Antoine
  • Paris
  • Ile-de-France
  • 75012
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
G49NDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2016
SIGHTENXTPA (Euronext Paris)YesOrdinary SharesFREURJul 2016
0RIMLSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2016
GSGT.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2016

Biography

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and ce ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:55
End of Day Share Price2019/06/10 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.